Year: 2014
Type: editorial
Abstract: In the article that accompanies this editorial, Mackey et al1 pres-ent the results of ROSE/TRIO-12, a randomized phase III trial com-paring single agent docetaxel to the combination of docetaxel and ramucirumab in front-line metastatic breast cancer. This large, well-powered, placebo-controlled international trial replaced bevacizumab (a vascular endothelial growth factor [VEGF] –A ligand blocking antibody used in numerous phase III trials) with ramucirumab (a human immunoglobulin G1 VEGF receptor [VEGFR] –2–binding monoclonal antibody recently approved for gastric cancer) as the anti-VEGF agent to be studied. The results are disappointing but familiar to those who have followed the story of anti-VEGF therapy in breast cancer—yet another failure. Bevacizumab, the first anti-VEGF therapy to enter the breast cancer arena, electrified the field in 2005 with the E2100 trial, which showed a doubling in progression-free survival (PFS) when combined
Source: Journal of Clinical Oncology
Author: George W. Sledge
Institutions: Stanford Medicine, Stanford University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funder: Genentech
OpenAlex ID: W2145761690
